Novanta Inc. Tangible Equity Units
NOVTU
NASDAQ Global Select62.68
USD
+1.06
- -
CIK
0001076930
ISIN
CA67000B2030
CUSIP
67000B203
Return %
Stock
S&P500
1Y
30.31
18.70
3Y
30.31
72.60
5Y
30.31
70.60
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Matthijs Glastra
- Full Time Employees
- 3,000
- Sector
- Technology
- Industry
- Hardware, Equipment & Parts
- Address
- 125 Middlesex Turnpike Bedford MA United States of America 01730
- IPO Date
- Mar 24, 1999
- CIK
- 0001076930
- Website
- novanta.com
- Similar Companies
- Business
- Novanta Inc. is a leading global supplier of proprietary technology solutions specializing in precision photonics, motion control components, and subsystems for medical, life science, bioprocessing, robotics, automation, and advanced industrial original equipment manufacturers. The company designs, develops, manufactures, and sells products that include precision motion systems, laser systems, vision and photonics solutions, and advanced surgery components. Novanta serves diverse geographic markets worldwide with more than 700 engineers and over 25 locations globally, delivering integrated technology solutions that enable innovations in precision medicine, advanced manufacturing, and robotics. Founded in 1991 and headquartered in Bedford, Massachusetts, Novanta's product portfolio encompasses precision motion components, laser technologies, photonics modules, and automation systems that support medical devices, surgical systems, and manufacturing equipment. The company targets original equipment manufacturers in medical technology, life sciences, bioprocessing, and industrial sectors. Novanta integrates deep proprietary expertise in these technologies to deliver high-performance solutions tailored to complex applications requiring extreme precision. Recent major changes include Novanta's public offering in November 2025 of 11 million Tangible Equity Units (Ticker: NOVTU) on Nasdaq, raising $550 million to strengthen the balance sheet and enhance strategic flexibility. This offering includes a prepaid stock purchase contract and a senior amortizing note due in 2028, with plans to use proceeds for debt repayment, working capital, acquisitions, and other corporate purposes. In 2024, Novanta launched multiple new products expected to ramp in 2025, aiming for approximately $1 billion in revenue with continued focus on margin expansion and acquisition-driven growth. The company reported solid financial results in 2024 with an 8% revenue increase to $949 million and strong cash flow generation supporting its strategic goals. Novanta operates through subsidiaries and focuses on innovation in precision medicine and manufacturing technologies, leveraging its global footprint to serve customers effectively. The company maintains a commitment to ethical business practices and continuous technological advancement to retain its market-leading position. The combination of precision photonics, motion control, laser, and vision technologies defines Novanta’s core competencies, making it a trusted partner in critical technology applications worldwide.
Company News
Novanta Inc. (NOVT) Q1 2026 Earnings Call Transcript